Aura Biosciences, Inc.
AURADrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 12, 2026
5wMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
How AURA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bel-sar | Phase 3 | Choroidal Melanoma | - | - |
Light-activated AU-011 | Phase 2 | Uveal Melanoma | - | - |
AU-011 | Phase 2 | Eye Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aura Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Aura Biosciences, Inc.'s (AURA) pipeline across Phase 3, Phase 2. Its lead program is Bel-sar (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aura Biosciences, Inc.'s next FDA catalyst?→
Aura Biosciences, Inc.'s (AURA) next tracked catalyst is a Phase 3 expected June 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AURA biotech catalysts?→
Add AURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aura Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.